ERBB2 and cancer: Considering that there are 19,620 new cases of breast cancer annually (based on data from the Polish National Cancer Registry for 2019) [1] and that preinvasive cancer occurs in 7% to 10% of these patients [6], the annual incidence of HR-positive, HER2-negative breast cancer in Poland can be estimated at 12,500 people.